{
  "disease_name": "Fabry disease",
  "orpha_code": "324",
  "drugs": [
    {
      "name": "GALAFOLD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/624875?name=324&mode=orpha&region=",
      "regulatory_id": "624875",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "GALAFOLD(Tradename                        - 23/07/2021)Disease(s) concernedORPHA:324 Fabry disease",
        "GALAFOLD(Tradename                        - 23/07/2021)",
        "(Tradename                        - 23/07/2021)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/459564?name=324&mode=orpha&region=&status=all",
          "text": "GALAFOLD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/624875?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "GALAFOLD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/459565?name=324&mode=orpha&region=",
      "regulatory_id": "459565",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "GALAFOLD(Tradename                        - 26/05/2016)Disease(s) concernedORPHA:324 Fabry disease",
        "GALAFOLD(Tradename                        - 26/05/2016)",
        "(Tradename                        - 26/05/2016)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/459564?name=324&mode=orpha&region=&status=all",
          "text": "GALAFOLD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/459565?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "ELFABRIO",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/650350?name=324&mode=orpha&region=",
      "regulatory_id": "650350",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "ELFABRIO(Tradename                        - 04/05/2023)Disease(s) concernedORPHA:324 Fabry disease",
        "ELFABRIO(Tradename                        - 04/05/2023)",
        "(Tradename                        - 04/05/2023)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/650349?name=324&mode=orpha&region=&status=all",
          "text": "ELFABRIO",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/650350?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "REPLAGAL",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/131342?name=324&mode=orpha&region=",
      "regulatory_id": "131342",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "REPLAGAL(Tradename                        - 03/08/2001)Disease(s) concernedORPHA:324 Fabry disease",
        "REPLAGAL(Tradename                        - 03/08/2001)",
        "(Tradename                        - 03/08/2001)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/34251?name=324&mode=orpha&region=&status=all",
          "text": "REPLAGAL",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131342?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "FABRAZYME",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/131340?name=324&mode=orpha&region=",
      "regulatory_id": "131340",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "FABRAZYME(Tradename                        - 03/08/2001)Disease(s) concernedORPHA:324 Fabry disease",
        "FABRAZYME(Tradename                        - 03/08/2001)",
        "(Tradename                        - 03/08/2001)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/33469?name=324&mode=orpha&region=&status=all",
          "text": "FABRAZYME",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131340?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Alpha galactosidase A",
      "substance_url": "/en/drug/substance/604987?name=324&mode=orpha&region=&status=all",
      "substance_id": "604987",
      "regulatory_url": "/en/drug/regulatory/604988?name=324&mode=orpha&region=",
      "regulatory_id": "604988",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Alpha galactosidase A(Medicinal product                        - 06/01/2021)Disease(s) concernedORPHA:324 Fabry disease",
        "Alpha galactosidase A(Medicinal product                        - 06/01/2021)",
        "(Medicinal product                        - 06/01/2021)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/604987?name=324&mode=orpha&region=&status=all",
          "text": "Alpha galactosidase A",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/604988?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA",
      "substance_url": "/en/drug/substance/588539?name=324&mode=orpha&region=&status=all",
      "substance_id": "588539",
      "regulatory_url": "/en/drug/regulatory/588540?name=324&mode=orpha&region=",
      "regulatory_id": "588540",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 28/02/2020)Disease(s) concernedORPHA:324 Fabry disease",
        "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 28/02/2020)",
        "(Medicinal product                        - 28/02/2020)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588539?name=324&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/588540?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA",
      "substance_url": "/en/drug/substance/588863?name=324&mode=orpha&region=&status=all",
      "substance_id": "588863",
      "regulatory_url": "/en/drug/regulatory/588865?name=324&mode=orpha&region=",
      "regulatory_id": "588865",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 09/01/2020)Disease(s) concernedORPHA:324 Fabry disease",
        "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 09/01/2020)",
        "(Medicinal product                        - 09/01/2020)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588863?name=324&mode=orpha&region=&status=all",
          "text": "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/588865?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene",
      "substance_url": "/en/drug/substance/487922?name=324&mode=orpha&region=&status=all",
      "substance_id": "487922",
      "regulatory_url": "/en/drug/regulatory/487926?name=324&mode=orpha&region=",
      "regulatory_id": "487926",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene(Medicinal product                        - 20/03/2017)Disease(s) concernedORPHA:324 Fabry disease",
        "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene(Medicinal product                        - 20/03/2017)",
        "(Medicinal product                        - 20/03/2017)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/487922?name=324&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/487926?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Venglustat",
      "substance_url": "/en/drug/substance/406512?name=324&mode=orpha&region=&status=all",
      "substance_id": "406512",
      "regulatory_url": "/en/drug/regulatory/411828?name=324&mode=orpha&region=",
      "regulatory_id": "411828",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Venglustat(Medicinal product                        - 22/08/2014)Disease(s) concernedORPHA:324 Fabry disease",
        "Venglustat(Medicinal product                        - 22/08/2014)",
        "(Medicinal product                        - 22/08/2014)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/406512?name=324&mode=orpha&region=&status=all",
          "text": "Venglustat",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/411828?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Lucerastat",
      "substance_url": "/en/drug/substance/317192?name=324&mode=orpha&region=&status=all",
      "substance_id": "317192",
      "regulatory_url": "/en/drug/regulatory/327068?name=324&mode=orpha&region=",
      "regulatory_id": "327068",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Lucerastat(Medicinal product                        - 09/08/2012)Disease(s) concernedORPHA:324 Fabry disease",
        "Lucerastat(Medicinal product                        - 09/08/2012)",
        "(Medicinal product                        - 09/08/2012)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/317192?name=324&mode=orpha&region=&status=all",
          "text": "Lucerastat",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/327068?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Migalastat hydrochloride",
      "substance_url": "/en/drug/substance/89184?name=324&mode=orpha&region=&status=all",
      "substance_id": "89184",
      "regulatory_url": "/en/drug/regulatory/134045?name=324&mode=orpha&region=",
      "regulatory_id": "134045",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Migalastat hydrochloride(Medicinal product                        - 22/05/2006)Disease(s) concernedORPHA:324 Fabry disease",
        "Migalastat hydrochloride(Medicinal product                        - 22/05/2006)",
        "(Medicinal product                        - 22/05/2006)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/89184?name=324&mode=orpha&region=&status=all",
          "text": "Migalastat hydrochloride",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/134045?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated virus serotype C102 containing the human GLA gene",
      "substance_url": "/en/drug/substance/628415?name=324&mode=orpha&region=&status=all",
      "substance_id": "628415",
      "regulatory_url": "/en/drug/regulatory/628416?name=324&mode=orpha&region=",
      "regulatory_id": "628416",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Adeno-associated virus serotype C102 containing the human GLA gene(Medicinal product                        - 13/04/2022)Disease(s) concernedORPHA:324 Fabry disease",
        "Adeno-associated virus serotype C102 containing the human GLA gene(Medicinal product                        - 13/04/2022)",
        "(Medicinal product                        - 13/04/2022)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/628415?name=324&mode=orpha&region=&status=all",
          "text": "Adeno-associated virus serotype C102 containing the human GLA gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/628416?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha",
      "substance_url": "/en/drug/substance/604880?name=324&mode=orpha&region=&status=all",
      "substance_id": "604880",
      "regulatory_url": "/en/drug/regulatory/604881?name=324&mode=orpha&region=",
      "regulatory_id": "604881",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:324 Fabry disease",
        "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha(Medicinal product                        - 19/10/2020)",
        "(Medicinal product                        - 19/10/2020)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/604880?name=324&mode=orpha&region=&status=all",
          "text": "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/604881?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Pegunigalsidase alfa",
      "substance_url": "/en/drug/substance/500669?name=324&mode=orpha&region=&status=all",
      "substance_id": "500669",
      "regulatory_url": "/en/drug/regulatory/500671?name=324&mode=orpha&region=",
      "regulatory_id": "500671",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Pegunigalsidase alfa(Medicinal product                        - 12/12/2017)Disease(s) concernedORPHA:324 Fabry disease",
        "Pegunigalsidase alfa(Medicinal product                        - 12/12/2017)",
        "(Medicinal product                        - 12/12/2017)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/500669?name=324&mode=orpha&region=&status=all",
          "text": "Pegunigalsidase alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/500671?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Agalsidase beta",
      "substance_url": "/en/drug/substance/33470?name=324&mode=orpha&region=&status=all",
      "substance_id": "33470",
      "regulatory_url": "/en/drug/regulatory/133689?name=324&mode=orpha&region=",
      "regulatory_id": "133689",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Agalsidase beta(Medicinal product                        - 08/08/2000)Disease(s) concernedORPHA:324 Fabry disease",
        "Agalsidase beta(Medicinal product                        - 08/08/2000)",
        "(Medicinal product                        - 08/08/2000)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/33470?name=324&mode=orpha&region=&status=all",
          "text": "Agalsidase beta",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/133689?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Agalsidase alfa",
      "substance_url": "/en/drug/substance/34115?name=324&mode=orpha&region=&status=all",
      "substance_id": "34115",
      "regulatory_url": "/en/drug/regulatory/133688?name=324&mode=orpha&region=",
      "regulatory_id": "133688",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Agalsidase alfa(Medicinal product                        - 08/08/2000)Disease(s) concernedORPHA:324 Fabry disease",
        "Agalsidase alfa(Medicinal product                        - 08/08/2000)",
        "(Medicinal product                        - 08/08/2000)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/34115?name=324&mode=orpha&region=&status=all",
          "text": "Agalsidase alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/133688?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "FABRAZYME",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/622163?name=324&mode=orpha&region=",
      "regulatory_id": "622163",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "FABRAZYME(Tradename                        - 11/03/2021)Disease(s) concernedORPHA:324 Fabry disease",
        "FABRAZYME(Tradename                        - 11/03/2021)",
        "(Tradename                        - 11/03/2021)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/33469?name=324&mode=orpha&region=&status=all",
          "text": "FABRAZYME",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/622163?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "GALAFOLD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/527546?name=324&mode=orpha&region=",
      "regulatory_id": "527546",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "GALAFOLD(Tradename                        - 10/08/2018)Disease(s) concernedORPHA:324 Fabry disease",
        "GALAFOLD(Tradename                        - 10/08/2018)",
        "(Tradename                        - 10/08/2018)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/459564?name=324&mode=orpha&region=&status=all",
          "text": "GALAFOLD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/527546?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)",
      "substance_url": "/en/drug/substance/691429?name=324&mode=orpha&region=&status=all",
      "substance_id": "691429",
      "regulatory_url": "/en/drug/regulatory/691596?name=324&mode=orpha&region=",
      "regulatory_id": "691596",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)(Medicinal product                        - 04/11/2024)Disease(s) concernedORPHA:324 Fabry disease",
        "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)(Medicinal product                        - 04/11/2024)",
        "(Medicinal product                        - 04/11/2024)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/691429?name=324&mode=orpha&region=&status=all",
          "text": "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/691596?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A",
      "substance_url": "/en/drug/substance/688294?name=324&mode=orpha&region=&status=all",
      "substance_id": "688294",
      "regulatory_url": "/en/drug/regulatory/688382?name=324&mode=orpha&region=",
      "regulatory_id": "688382",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A(Medicinal product                        - 19/09/2024)Disease(s) concernedORPHA:324 Fabry disease",
        "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A(Medicinal product                        - 19/09/2024)",
        "(Medicinal product                        - 19/09/2024)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/688294?name=324&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/688382?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein",
      "substance_url": "/en/drug/substance/676680?name=324&mode=orpha&region=&status=all",
      "substance_id": "676680",
      "regulatory_url": "/en/drug/regulatory/676731?name=324&mode=orpha&region=",
      "regulatory_id": "676731",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein(Medicinal product                        - 24/05/2024)Disease(s) concernedORPHA:324 Fabry disease",
        "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein(Medicinal product                        - 24/05/2024)",
        "(Medicinal product                        - 24/05/2024)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/676680?name=324&mode=orpha&region=&status=all",
          "text": "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/676731?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene",
      "substance_url": "/en/drug/substance/662638?name=324&mode=orpha&region=&status=all",
      "substance_id": "662638",
      "regulatory_url": "/en/drug/regulatory/662837?name=324&mode=orpha&region=",
      "regulatory_id": "662837",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene(Medicinal product                        - 15/02/2024)Disease(s) concernedORPHA:324 Fabry disease",
        "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene(Medicinal product                        - 15/02/2024)",
        "(Medicinal product                        - 15/02/2024)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/662638?name=324&mode=orpha&region=&status=all",
          "text": "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/662837?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme",
      "substance_url": "/en/drug/substance/663118?name=324&mode=orpha&region=&status=all",
      "substance_id": "663118",
      "regulatory_url": "/en/drug/regulatory/663434?name=324&mode=orpha&region=",
      "regulatory_id": "663434",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme(Medicinal product                        - 19/09/2023)Disease(s) concernedORPHA:324 Fabry disease",
        "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme(Medicinal product                        - 19/09/2023)",
        "(Medicinal product                        - 19/09/2023)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/663118?name=324&mode=orpha&region=&status=all",
          "text": "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/663434?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A",
      "substance_url": "/en/drug/substance/666382?name=324&mode=orpha&region=&status=all",
      "substance_id": "666382",
      "regulatory_url": "/en/drug/regulatory/666434?name=324&mode=orpha&region=",
      "regulatory_id": "666434",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A(Medicinal product                        - 11/08/2023)Disease(s) concernedORPHA:324 Fabry disease",
        "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A(Medicinal product                        - 11/08/2023)",
        "(Medicinal product                        - 11/08/2023)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/666382?name=324&mode=orpha&region=&status=all",
          "text": "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/666434?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene",
      "substance_url": "/en/drug/substance/645663?name=324&mode=orpha&region=&status=all",
      "substance_id": "645663",
      "regulatory_url": "/en/drug/regulatory/645664?name=324&mode=orpha&region=",
      "regulatory_id": "645664",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene(Medicinal product                        - 09/03/2020)Disease(s) concernedORPHA:324 Fabry disease",
        "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene(Medicinal product                        - 09/03/2020)",
        "(Medicinal product                        - 09/03/2020)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/645663?name=324&mode=orpha&region=&status=all",
          "text": "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/645664?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Venglustat",
      "substance_url": "/en/drug/substance/406512?name=324&mode=orpha&region=&status=all",
      "substance_id": "406512",
      "regulatory_url": "/en/drug/regulatory/413140?name=324&mode=orpha&region=",
      "regulatory_id": "413140",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Venglustat(Medicinal product                        - 26/08/2014)Disease(s) concernedORPHA:324 Fabry disease",
        "Venglustat(Medicinal product                        - 26/08/2014)",
        "(Medicinal product                        - 26/08/2014)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/406512?name=324&mode=orpha&region=&status=all",
          "text": "Venglustat",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/413140?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Venglustat",
      "substance_url": "/en/drug/substance/406512?name=324&mode=orpha&region=&status=all",
      "substance_id": "406512",
      "regulatory_url": "/en/drug/regulatory/413138?name=324&mode=orpha&region=",
      "regulatory_id": "413138",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Venglustat(Medicinal product                        - 26/08/2014)Disease(s) concernedORPHA:324 Fabry disease",
        "Venglustat(Medicinal product                        - 26/08/2014)",
        "(Medicinal product                        - 26/08/2014)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/406512?name=324&mode=orpha&region=&status=all",
          "text": "Venglustat",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/413138?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Migalastat hydrochloride",
      "substance_url": "/en/drug/substance/89184?name=324&mode=orpha&region=&status=all",
      "substance_id": "89184",
      "regulatory_url": "/en/drug/regulatory/132138?name=324&mode=orpha&region=",
      "regulatory_id": "132138",
      "orpha_substance_code": "ORPHA:324",
      "details": [
        "Migalastat hydrochloride(Medicinal product                        - 25/02/2004)Disease(s) concernedORPHA:324 Fabry disease",
        "Migalastat hydrochloride(Medicinal product                        - 25/02/2004)",
        "(Medicinal product                        - 25/02/2004)",
        "Disease(s) concernedORPHA:324 Fabry disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/89184?name=324&mode=orpha&region=&status=all",
          "text": "Migalastat hydrochloride",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/324",
          "text": "ORPHA:324 Fabry disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/132138?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=324&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=324&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=324&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=324&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=324&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=324&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=324&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=324&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=324&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=324&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=324&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=324&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=324&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=324&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=324&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=324&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=324&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=324&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=324&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=324&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=324&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=324&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=324&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=324&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=324&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=324&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=324&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=324&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=324&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T05:59:57.549350",
  "run_number": 1,
  "total_drugs_found": 39,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Fabry+disease&orphaCode=324&name=324&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Fabry disease",
    "orphaCode": "324",
    "name": "324",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}